This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fausch, S. C. Articles by Kast, W. M. Search for Related Content PubMed PubMed Citation Articles by Fausch, S. C. Articles by Kast, W. M.

Differential Uptake and Cross-Presentation of Human Papillomavirus Virus-like Particles by Dendritic Cells and Langerhans Cells¹

Cancer Immunology Program, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, Illinois 60153

A causal link between cervical cancer and high-risk human papillomaviruses has been established. The virus infects basal cells of the mucosa, where Langerhans cells are the resident antigen-presenting cells. Langerhans cells and dendritic cells, which are targeted by vaccination, internalize similar amounts of human papillomavirus virus-like particles (VLPs), albeit through different uptake mechanisms. VLP uptake by dendritic cells results in activation and cross-presentation of MHC class I-restricted peptides with costimulation to T cells. Conversely, VLP uptake by Langerhans cells leads to cross-presentation in the absence of costimulation. Efficient VLP cross-presentation by Langerhans cells with costimulation can be achieved by addition of CD40 ligand. The lack of a protective immune response after viral contact with Langerhans cells may explain why some women fail to mount an immune response against the virus or why the immune responses that do develop may allow the virus to persist. Because VLPs are currently being tested as a vaccine against cervical cancer, our data are very topical and have implications for optimal vaccination strategies against this disease.

This article has been cited by other articles:

				A. Garcia-Pineres, A. Hildesheim, L. Dodd, T. J. Kemp, M. Williams, C. Harro, D. R. Lowy, J. T. Schiller, and L. A. Pinto Cytokine and Chemokine Profiles following Vaccination with Human Papillomavirus Type 16 L1 Virus-Like Particles Clin. Vaccine Immunol., August 1, 2007; 14(8): 984 - 989. [Abstract] [Full Text] [PDF]

				D. M. Da Silva, S. C. Fausch, J. S. Verbeek, and W. M. Kast Uptake of Human Papillomavirus Virus-Like Particles by Dendritic Cells Is Mediated by Fc{gamma} Receptors and Contributes to Acquisition of T Cell Immunity J. Immunol., June 15, 2007; 178(12): 7587 - 7597. [Abstract] [Full Text] [PDF]

				L. Buonaguro, M. L. Tornesello, M. Tagliamonte, R. C. Gallo, L. X. Wang, R. Kamin-Lewis, S. Abdelwahab, G. K. Lewis, and F. M. Buonaguro Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses. J. Virol., September 1, 2006; 80(18): 9134 - 9143. [Abstract] [Full Text] [PDF]

				R. Yang, C. M. Wheeler, X. Chen, S. Uematsu, K. Takeda, S. Akira, D. V. Pastrana, R. P. Viscidi, and R. B. S. Roden Papillomavirus Capsid Mutation To Escape Dendritic Cell-Dependent Innate Immunity in Cervical Cancer J. Virol., June 1, 2005; 79(11): 6741 - 6750. [Abstract] [Full Text] [PDF]

				S. C. Fausch, L. M. Fahey, D. M. Da Silva, and W. M. Kast Human Papillomavirus Can Escape Immune Recognition through Langerhans Cell Phosphoinositide 3-Kinase Activation J. Immunol., June 1, 2005; 174(11): 7172 - 7178. [Abstract] [Full Text] [PDF]

				L. Bousarghin, P. Hubert, E. Franzen, N. Jacobs, J. Boniver, and P. Delvenne Human papillomavirus 16 virus-like particles use heparan sulfates to bind dendritic cells and colocalize with langerin in Langerhans cells J. Gen. Virol., May 1, 2005; 86(5): 1297 - 1305. [Abstract] [Full Text] [PDF]

				N. Imelli, O. Meier, K. Boucke, S. Hemmi, and U. F. Greber Cholesterol Is Required for Endocytosis and Endosomal Escape of Adenovirus Type 2 J. Virol., March 15, 2004; 78(6): 3089 - 3098. [Abstract] [Full Text] [PDF]